Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements - Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...